Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tragara sees peachy Capoxigem future even as APRiCOT trial fails overall in NSCLC

This article was originally published in Scrip

Executive Summary

San Diego-based Tragara Pharmaceuticals is focusing on positive data from a subset of patients after a Phase II trial investigating its oral once-daily COX-2 inhibitor, Capoxigem (apricoxib; TG01), in combination with erlotinib in patients with non-small cell lung cancer (NSCLC) failed to meet the primary endpoint in the overall study population.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC013310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel